According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
A number of other research firms have also commented on PBMD. FBR & Co set a $6.00 price target on shares of Prima BioMed and gave the stock a buy rating in a research report on Thursday, September 8th. Maxim Group reaffirmed a buy rating on shares of Prima BioMed in a research report on Wednesday, June 22nd. HC Wainwright reaffirmed a buy rating on shares of Prima BioMed in a research report on Wednesday, June 22nd. Finally, Roth Capital reaffirmed a buy rating and set a $6.00 price target on shares of Prima BioMed in a research report on Friday, August 26th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Prima BioMed currently has a consensus rating of Buy and an average target price of $4.20.
Shares of Prima BioMed (NASDAQ:PBMD) traded down 0.562% during mid-day trading on Thursday, hitting $0.885. 12,446 shares of the stock traded hands. The company’s 50 day moving average is $0.87 and its 200 day moving average is $0.95. The firm’s market capitalization is $60.82 million. Prima BioMed has a one year low of $0.72 and a one year high of $1.54.
Prima BioMed Company Profile
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.